High-throughput Drug Discovery Applications for Supercritical Fluid Chromatography-Mass Spectrometry
Feb 1, 2005
By: Yining Zhao, Pat Sandra, Gregory Woo, Samuel Thomas, Kyung Gahm, David Semin
This article describes the pros and cons of pSFC-MS and attempts to demonstrate its broad applicability to such fields as high-throughput analysis, purity assessment, structure characterization and purification. An outlook for the future of this technique also is presented.
Build vs. Buy vs. Both
Jan 27, 2005
By: Daniel C. Weaver
To contain costs and optimize performance, most drug discovery companies are faced with questions of "Build" vs. "Buy" with regard to their informatics systems. Here, the author describes an alternative: the hybrid "Both" approach to the software system development process.
Getting More out of Public Microarray Data
Jan 27, 2005
By: Joel Parker
Current investigations into the transcriptome have yielded a vast amount of publicly available data, but the diversity of technologies used to isolate, purify, label and measure RNA can make it difficult to combine experiments. This month, guest author Joel Parker discusses successful methods for mining information from disparate data sets.
How Multiplexed Arrays Enable Large-scale Studies
Jan 27, 2005
By: John J. Kang, S. Shawn Dastmalchi, Ezra Abrams, Brian Patterson, J. Michael Collier
Discovery programs are beginning to incorporate hypothesis-driven research that calls for testing against large sample populations. This article describes how multiplexed arrays enable such an industrial approach to parallel analysis of target genes across large numbers of samples while offering improved reproducibility.
Is Genomics Advancing Drug Discovery?
Jan 27, 2005
By: Lukas K. Buehler
Genomics has opened new ways of scrutinizing genes, which as created immense enthusiasm because of the potential of finding new cures for human diseases. here, our columnist explores the obstacles to the development and approval of novel drugs, and how we can overcome them through genomics.
Laboratory Informatics and Financial Performance: A Meeting of Minds
Oct 1, 2004
By: Gordon W. Logan
In this installment of our Metrics and management column, Gordon Logan examines a subtle but significant approach used by investors to ask not only what money is being spent but also how it is being spent.
The Future of Microarray Readers
Oct 1, 2004
By: Julian White
The author investigates the development of microarray technology and, particularly, the use of microarray readers in healthcare applications. The various elements of current reader technology are reviewed and used to predict the composition of readers for diagnostics and screening.
Toxicology Biomarkers in Drug Development
Oct 1, 2004
By: Timothy P. Ryan, David E. Watson, Brian R. Berridge
Now that the industry is immersed in microarray and other genomic technologies, a new strategic direction is needed to bring decision-based toxicology to its full potential. This review focuses on short-term strategies to increase return-on-investment when applying these technologies to better identify candidate toxicology biomarkers.
Banking on Swiss Biotechnology
Aug 31, 2004
By: Jodi Harris
As a renowned financial capital of the world, Switzerland ranks highly on many economic fronts. Now, the Swiss government has set its sights on establishing the country's role as a leader on a new frontier: life science and biotechnology innovation.
|
